THE ABSENCE OF A PHARMACOKINETIC INTERACTION BETWEEN ASPIRIN AND THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR BENAZEPRIL IN HEALTHY-VOLUNTEERS

被引：3

作者：

SIOUFI, A ^{[1
]}

POMMIER, F ^{[1
]}

GAUDUCHEAU, N ^{[1
]}

GODBILLON, J ^{[1
]}

CHOI, L ^{[1
]}

JOHN, V ^{[1
]}

机构：

[1] CIBA GEIGY CORP,DIV PHARMACEUT,CLIN PHARMACOKINET & DISPOSIT,ARDSLEY,NY 10502

来源：

BIOPHARMACEUTICS & DRUG DISPOSITION | 1994年 / 15卷 / 06期

关键词：

BENAZEPRIL; BENAZEPRILAT; ASPIRIN; PHARMACOKINETICS; INTERACTION; SINGLE DOSE; HEALTHY VOLUNTEERS;

D O I：

10.1002/bdd.2510150603

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Potential effects of the coadministration of single doses of aspirin (325 mg) and of benazepril hydrochloride (20 mg) on the pharmacokinetics and the metabolism of these two drugs were evaluated in 12 healthy subjects. Plasma concentration profiles of benazepril, its active metabolite benazeprilat, and total salicylic acid were determined together with urinary excretion of benazeprilat, salicylic acid, salicyluric acid, and salicylate glucuronides. Almost superimposable plasma profiles of benazepril, benazeprilat, and total salicylic acid were achieved with the drugs given alone and concomitantly. The coadministration of benazepril hydrochloride and aspirin did not modify the pharmacokinetics or the metabolism of the two drugs.

引用

页码：451 / 461

页数：11

共 27 条

[1] DETERMINATION OF ASPIRIN, SALICYLIC-ACID, SALICYLURIC ACID, AND GENTISIC ACID IN HUMAN-PLASMA AND URINE BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY [J].

AMICK, EN ;

MASON, WD .

ANALYTICAL LETTERS, 1979, 12 (06) :629-640

[2] INTERACTION BETWEEN FUROSEMIDE AND THE CONVERTING ENZYME-INHIBITOR BENAZEPRIL IN HEALTHY-VOLUNTEERS [J].

DELEPELEIRE, I ;

VANHECKEN, A ;

VERBESSELT, R ;

KAISER, G ;

BARNER, A ;

HOLMES, I ;

DESCHEPPER, PJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :465-468

[3]

DRESSE A, 1992, J NEW DEV CLIN ME S1, V10, P15

[4] BAYESIAN-APPROACH TO BIOEQUIVALENCE ASSESSMENT - AN EXAMPLE [J].

FLUEHLER, H ;

GRIEVE, AP ;

MANDALLAZ, D ;

MAU, J ;

MOSER, HA .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (10) :1178-1181

[5] THE PHARMACOKINETICS OF BENAZEPRIL RELATIVE TO OTHER ACE INHIBITORS [J].

GENGO, FM ;

BRADY, E .

CLINICAL CARDIOLOGY, 1991, 14 (08) :44-50

[6]

HITZENBERGER G, 1992, J NEW DEV CLIN ME S1, V10, P85

[7]

HITZENBERGER G, 1992, J NEW DEV CLIN ME S1, V10, P69

[8] THE INFLUENCE OF HEPATIC CIRRHOSIS ON THE PHARMACOKINETICS OF BENAZEPRIL HYDROCHLORIDE [J].

KAISER, G ;

ACKERMANN, R ;

GSCHWIND, HP ;

JAMES, IM ;

SPRENGERS, D ;

MCINTYRE, N ;

DEFALCO, A ;

HOLMES, IB .

BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (09) :753-764

[9] PHARMACOKINETICS OF A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR, BENAZEPRIL HYDROCHLORIDE, IN SPECIAL POPULATIONS [J].

KAISER, G ;

ACKERMANN, R ;

SIOUFI, A .

AMERICAN HEART JOURNAL, 1989, 117 (03) :746-751

[10] PHARMACOKINETICS OF THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR BENAZEPRIL.HCL (CGS-14-824-A) IN HEALTHY-VOLUNTEERS AFTER SINGLE AND REPEATED ADMINISTRATION [J].

KAISER, G ;

ACKERMANN, R ;

BRECHBUHLER, S ;

DIETERLE, W .

BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (04) :365-376

← 1 2 3 →